Cargando…

Downstaging and Pathological Complete Response of Locally Recurrent Sarcomatoid Renal Cell Carcinoma under Pembrolizumab and Lenvatinib: A Case Report and Review of Literature

The advent of immune checkpoint inhibition opened new perspectives for patients with recurrent or metastasized renal cell carcinoma. In case of recurrent disease, surgical resection remains the most promising therapeutic option. Surgical resection is associated with improved overall survival and dem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ell, Jascha, Balz, Philipp, Manava, Panagiota, Hüttenbrink, Clemens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616667/ https://www.ncbi.nlm.nih.gov/pubmed/37915993 http://dx.doi.org/10.1159/000534000

Ejemplares similares

Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report
por: Liu, Zhaobo, et al.
Publicado: (2020)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Axitinib for preoperative downstaging of renal cell carcinoma with sarcomatoid differentiation and direct invasion of the duodenum and inferior vena cava: a case report
por: Yuki, Hideo, et al.
Publicado: (2014)

Combined use of pembrolizumab and lenvatinib: A review
por: Eisinger, Casey, et al.
Publicado: (2023)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
por: Mehta, Naaman, et al.
Publicado: (2023)

Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
por: Liu, Zhaonan, et al.
Publicado: (2019)

Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma
por: Leidner, Rom, et al.
Publicado: (2021)

Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
por: Wang, Ye, et al.
Publicado: (2022)

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
por: Shintani, Hiroshi, et al.
Publicado: (2021)

Rapid recurrence and radiographic progression of sarcomatoid renal cell carcinoma
por: Edelson, Mia P., et al.
Publicado: (2017)

Nomogram for predicting pathological complete response and tumor downstaging in patients with locally advanced rectal cancer on the basis of a randomized clinical trial
por: Zhang, Jian-Wei, et al.
Publicado: (2020)

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma
por: Bedrose, Sara, et al.
Publicado: (2020)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

Lenvatinib plus pembrolizumab a new effective combination of targeted agents
por: Perez-Fidalgo, J.A., et al.
Publicado: (2023)

Urinary Exosomes from Bladder Cancer Patients Show a Residual Cancer Phenotype despite Complete Pathological Downstaging
por: Hiltbrunner, Stefanie, et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
por: Eto, Masatoshi, et al.
Publicado: (2022)

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
por: Dierks, Christine, et al.
Publicado: (2021)

Favourable outcome of pathologic downstaging by locoregional treatment for hepatocellular carcinoma in liver transplantation
por: Kim, Deok Gie, et al.
Publicado: (2019)

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
por: Finn, Richard S., et al.
Publicado: (2020)

Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma
por: Wu, Chi-Jung, et al.
Publicado: (2022)

Rationale Efficacy and Safety Evidence of Lenvatinib and Pembrolizumab Association in Anaplastic Thyroid Carcinoma
por: Boudin, Laurys, et al.
Publicado: (2022)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2023)

Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab
por: Motzer, Robert, et al.
Publicado: (2023)

The Pathology and Molecular Genetics of Sarcomatoid Renal Cell Carcinoma: A Mini-Review
por: Wei, Shuanzeng, et al.
Publicado: (2017)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
por: Grünwald, Viktor, et al.
Publicado: (2023)

Clinical Benefit from Lenvatinib and Pembrolizumab Observed in Mullerian Adenosarcoma: A Case Report
por: Alcindor, Thierry, et al.
Publicado: (2021)

Infection as a Differential Diagnosis of Solid Retroperitoneal Masses: A Case Series and Review of the Literature
por: Levidou, Georgia, et al.
Publicado: (2022)

Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
por: Fukuta, Kyotaro, et al.
Publicado: (2021)

AB185. Clinical and pathological features of sarcomatoid carcinoma of the renal pelvis and literature review
por: Liu, Xiaoteng
Publicado: (2016)

A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab
por: Tomioka, Masayuki, et al.
Publicado: (2021)

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib
por: Boustany, Johnny, et al.
Publicado: (2020)

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
por: Sato, Hiroaki, et al.
Publicado: (2023)

Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
por: Makker, Vicky, et al.
Publicado: (2021)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
por: Shen, Sherry, et al.
Publicado: (2021)

PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer
por: Vodopivec, Danica M, et al.
Publicado: (2022)

Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
por: Fellouah, Massine, et al.
Publicado: (2023)

Pembrolizumab plus lenvatinib in advanced endometrial cancer: case report and systematic review of lung toxicity
por: Staropoli, Nicoletta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_q2sgg30doc94sg4ei7v83sc55l